DXCM vs. RMD

In the year-to-date period, DXCM achieves a 9.09% return, which is significantly higher than RMD's 3.69% return. Over the past 10 years, DXCM has outperformed RMD with an annualized return of 19.17%, while RMD has yielded a comparatively lower 16.11% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for DexCom, Inc. (DXCM) and ResMed Inc. (RMD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current DXCM Sharpe Ratio is -0.58, which is lower than the RMD Sharpe Ratio of 1.10. The chart below compares the historical Sharpe Ratios of DXCM and RMD, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

DXCM has not paid dividends to shareholders, while RMD's dividend yield for the trailing twelve months is around 0.85%.

The maximum DXCM drawdown since its inception was -94.61%, which is greater than RMD's maximum drawdown of -61.60%. Use the drawdown chart below to compare losses from any high point for DXCM and RMD. For additional features, visit the drawdowns tool.

DexCom, Inc. (DXCM) has a higher volatility of 10.89% compared to ResMed Inc. (RMD) at 7.94%. This indicates that DXCM's price experiences larger fluctuations and is considered to be riskier than RMD based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between DexCom, Inc. and ResMed Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.